Vir Biotechnology (VIR) has released an update.
Vir Biotechnology and GlaxoSmithKline have mutually agreed to terminate their collaboration on an influenza treatment program, initially established in May 2021. The termination releases Vir Biotechnology from its exclusive obligations regarding the program, allowing them to independently pursue the development and commercialization of their influenza products, including paying GSK low single-digit royalties on net sales. Despite this change, their broader collaboration agreement remains in effect.
For further insights into VIR stock, check out TipRanks’ Stock Analysis page.
